However, this HDAC inhibitor did not increase H3K27acet in the CCI-NB02-RPT PDX following vorinostat priming (Fig. 8E) and did not sensitize this relapse model to combination therapy, with no significant difference between these treatment arms for either tumor growth or survival time (Fig. 8F). The gene discussed is HDAC9; the disease is neoplasm.